These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 39332750)

  • 1. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.
    Wang Q; Yu J; Sun X; Li J; Cao S; Han Y; Wang H; Yang Z; Li J; Hu C; Zhang Y; Jin L
    Crit Rev Oncol Hematol; 2024 Sep; 204():104522. PubMed ID: 39332750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-Line Systemic Treatment Strategies for Unresectable Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Liu W; Quan B; Lu S; Tang B; Li M; Chen R; Ren Z; Yin X
    Front Oncol; 2021; 11():771045. PubMed ID: 35004289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of randomized controlled trials.
    Lu F; Zhao K; Ye M; Xing G; Liu B; Li X; Ran Y; Wu F; Chen W; Hu S
    BMC Cancer; 2024 Aug; 24(1):1023. PubMed ID: 39160484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of first-line treatments for advanced hepatocellular carcinoma patients: a systematic review and network meta-analysis.
    Li J; Yang B; Teng Z; Liu Y; Li D; Qu X
    Front Immunol; 2024; 15():1430196. PubMed ID: 39355238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Balancing Efficacy and Tolerability of First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
    Celsa C; Cabibbo G; Pinato DJ; Di Maria G; Enea M; Vaccaro M; Battaglia S; Rizzo GEM; Giuffrida P; Giacchetto CM; Rancatore G; Grassini MV; Cammà C
    Liver Cancer; 2024 Apr; 13(2):169-180. PubMed ID: 38751554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
    Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
    Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Liang Y; Gan L; Zeng D; Lin L; Xiong Z; Liao F; Wang A
    Clin Transl Oncol; 2024 Oct; 26(10):2652-2664. PubMed ID: 38671328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging therapies are reshaping the first-line treatment for advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Peng W; Pan Y; Xie L; Yang Z; Ye Z; Chen J; Wang J; Hu D; Xu L; Zhou Z; Chen M; Fang A; Zhang Y
    Therap Adv Gastroenterol; 2024; 17():17562848241237631. PubMed ID: 38645513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ranking of transarterial and targeted therapies for advanced hepatocellular carcinoma in the era of immuno-oncology: A network meta-analysis of randomized sorafenib-controlled trials.
    An J; Han S; Kim HI; Shim JH
    Hepatol Commun; 2022 Oct; 6(10):2886-2900. PubMed ID: 35785525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab in Combination with Bevacizumab for the Management of Patients with Hepatocellular Carcinoma in the First-Line Setting: Systematic Literature Review and Meta-Analysis.
    Vogel A; Finn RS; Blanchet Zumofen MH; Heuser C; Alvarez JS; Leibfried M; Mitchell CR; Batson S; Redhead G; Gaillard VE; Kudo M
    Liver Cancer; 2023 Dec; 12(6):510-520. PubMed ID: 38058419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of monotherapy and combination therapy of immune checkpoint inhibitors as first-line treatment for unresectable hepatocellular carcinoma: a systematic review, meta-analysis and network meta-analysis.
    Lei Q; Yan X; Zou H; Jiang Y; Lai Y; Ung COL; Hu H
    Discov Oncol; 2022 Sep; 13(1):95. PubMed ID: 36171533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy or targeted therapy as the first-line strategies for unresectable hepatocellular carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Liu K; Zhu Y; Zhu H
    Front Immunol; 2022; 13():1103055. PubMed ID: 36713376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of molecular targeted agents combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: a network meta-analysis.
    Long J; Chen B; Liu Z
    Front Oncol; 2023; 13():1179431. PubMed ID: 37265792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying optimal therapies in patients with advanced hepatocellular carcinoma: a systematic review and network meta-analysis.
    Yang Z; Tong Y; Yang L; He X; Bao G; Du X
    Transl Gastroenterol Hepatol; 2022; 7():38. PubMed ID: 36300147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network meta-analysis of efficacy and safety for first-line and maintenance therapies in patients with unresectable colorectal liver metastases.
    Jiang Y; Shao T; Zhao M; Xue Y; Zheng X
    Front Pharmacol; 2024; 15():1374136. PubMed ID: 39130637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.